← Back to Clinical Trials
Recruiting NCT06764576

NCT06764576 Patients With Tuberculosis, Mycobacteriosis or Latent Tuberculosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06764576
Status Recruiting
Phase
Sponsor IRCCS Azienda Ospedaliero-Universitaria di Bologna
Condition Mycobacterial Infection
Study Type OBSERVATIONAL
Enrollment 13,000 participants
Start Date 2021-12-19
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 13,000 participants in total. It began in 2021-12-19 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In the last 30 years, tuberculosis (TB) has re-emerged in industrialised countries as a public health, with a decrease in incidence among the resident population and an increase in the burden of immigrants. Therefore, it becomes a priority to implement an effective TB control that relies on both rapid and reliable identification of active infections, with a adequate treatment and surveillance of resistance, but also on the identification of latent tuberculosis infections (ITBL) in populations at higher risk of progression to the active disease, representing a source of infection for the community.

Eligibility Criteria

Inclusion Criteria: * age of 18 years or more, * clinical/radiological suspicion of TB or non-tubercular mycobacteriosis or ITBL for which sent to the Microbiology laboratory at least one biological sample for the mycobacteria and/or a blood sample for the IGRA test; * Obtaining informed consent. Exclusion Criteria: * None

Contact & Investigator

Central Contact

Paola Dal Monte, MD

✉ paola.dalmonte@unibo.it

📞 0390512145293

Principal Investigator

Paola Dal Monte, MD

PRINCIPAL INVESTIGATOR

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Frequently Asked Questions

Who can join the NCT06764576 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Mycobacterial Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06764576 currently recruiting?

Yes, NCT06764576 is actively recruiting participants. Contact the research team at paola.dalmonte@unibo.it for enrollment information.

Where is the NCT06764576 trial being conducted?

This trial is being conducted at Bologna, Italy.

Who is sponsoring the NCT06764576 clinical trial?

NCT06764576 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Paola Dal Monte, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 13,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology